RYTM News and Press, Rhythm Pharmaceuticals Inc. From 11/07/23

2023-11-07 07:08:17 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals Q3 2023 Earnings Preview Rhythm’s obesity therapy granted EU backing for orphan designation Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals For further details s...

-- Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 -...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Rhythm Pharmaceuticals Inc. (RYTM) is expected to report $-0.76 for Q3 2023

2023-11-06 14:46:10 ET More on Rhythm Pharmaceuticals Rhythm’s obesity therapy granted EU backing for orphan designation Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals Historical earnings data for Rhythm Pharmaceuticals Financial informa...

-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS)​ -- -- Recommendation based on demonstrated clinical benefit in Phase 3 trial -- BOSTON, Nov. 02, 2023 (GLOBE NE...

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwa...

2023-10-19 08:45:29 ET Palm Beach, FL – October 19, 2023 – FinancialNewsMedia.com News Commentary – The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in regulating energ...

2023-10-18 10:31:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The third quarter was ...

-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO weight classifications -- -- Additional lo...